...
首页> 外文期刊>Clinical chemistry and laboratory medicine: CCLM >Inflammatory bowel diseases: From pathogenesis to laboratory testing
【24h】

Inflammatory bowel diseases: From pathogenesis to laboratory testing

机译:炎症性肠病:从发病机理到实验室检查

获取原文
获取原文并翻译 | 示例

摘要

Inflammatory bowel diseases (IBDs), which comprise the two major clinical subtypes, Crohn's disease and ulcerative colitis, incur high morbidity and potential mortality. The present study reviews data on the pathogenesis and diagnosis of IBDs. The pathogenesis depends on complex interactions between susceptibility genes, environmental factors, and innate and adaptive immunity, the understanding of which is crucial to discovering novel laboratory biomarkers. Traditional laboratory tests for the diagnosis, prognosis and assessment of disease activity of IBDs are reported on, and the biochemical properties, preanalytical and analytical aspects and clinical utility of the fecal markers lactoferrin and calprotectin are described. DNA testing and established (ASCA and pANCA) and emerging (ACCA, ALCA, AMCA, OmpC) serum markers are described; a further aspect to be addressed is the clinical use of pharmacogenetics for the treatment of IBDs.
机译:炎症性肠病(IBDs)包括两种主要的临床亚型,克罗恩氏病和溃疡性结肠炎,其发病率高,潜在死亡率高。本研究综述了IBD的发病机理和诊断数据。发病机理取决于易感基因,环境因素以及先天性和适应性免疫之间的复杂相互作用,对此的理解对于发现新型实验室生物标记物至关重要。报告了对IBDs的疾病活性进行诊断,预后和评估的传统实验室测试,并描述了粪便标记物乳铁蛋白和钙卫蛋白的生化特性,分析前和分析方面以及临床实用性。描述了DNA测试和建立的(ASCA和pANCA)和新兴的(ACCA,ALCA,AMCA,OmpC)血清标志物;要解决的另一方面是药物遗传学在治疗IBD中的临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号